enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Purchases $19,717.50 in Stock

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) major shareholder Growth Opportunities F. Forbion bought 2,750 shares of the firm's stock in a transaction on Wednesday, December 27th. The shares were purchased at an average price of $7.17 per share, for a total transaction of $19,717.50. Following the purchase, the insider now owns 2,002,750 shares in the company, valued at $14,359,717.50. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.

enGene Price Performance

NASDAQ ENGN traded down $0.28 on Friday, reaching $9.02. The company had a trading volume of 110,205 shares, compared to its average volume of 113,105. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $398.38 million, a PE ratio of -5.24 and a beta of -0.69. The firm's 50 day moving average price is $6.66 and its 200 day moving average price is $9.83. enGene Holdings Inc. has a 12 month low of $4.42 and a 12 month high of $43.00.

enGene (NASDAQ:ENGN - Get Free Report) last announced its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.05. As a group, equities analysts predict that enGene Holdings Inc. will post -1.56 earnings per share for the current year.

Institutional Trading of enGene

A number of large investors have recently made changes to their positions in ENGN. Altitude Crest Partners Inc. bought a new stake in shares of enGene in the 1st quarter worth about $2,039,000. SR One Capital Management LP purchased a new position in shares of enGene during the 2nd quarter worth about $4,715,000. Logos Global Management LP boosted its stake in shares of enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company's stock worth $11,316,000 after purchasing an additional 400,000 shares during the period. Finally, Janus Henderson Group PLC purchased a new position in shares of enGene during the 1st quarter worth about $17,095,000. 64.16% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ENGN. Oppenheimer restated an "outperform" rating and set a $30.00 price objective on shares of enGene in a research report on Tuesday, September 24th. Morgan Stanley restated an "overweight" rating and set a $40.00 price objective on shares of enGene in a research report on Wednesday, September 11th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $33.67.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.